Therapy Areas: Autoimmune
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
21 October 2024 - Pharmaceutical company Accord Healthcare Limited, a subsidiary of Intas Pharmaceuticals, announced on Saturday that it has received a positive opinion from the Committee for Medicina...
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
16 October 2024 - Clinical stage biotechnology company Adicet Bio Inc (Nasdaq: ACET) announced on Wednesday that it has received FDA approval to amend its Investigational New Drug (IND) application to...
Cantargia reports positive safety and biomarker results in CAN10 phase 1 trial
11 October 2024 - Swedish biotechnology company Cantargia AB (STO:CANTA) on Friday reported promising new data from the ongoing CAN10 phase 1 clinical study.All 68 participants receiving a single dose...
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
3 October 2024 - Pharmaceutical company H. Lundbeck A/S (CPH:HLUN) announced on Thursday the initiation of a clinical trial for its CD40L blocker, Lu AG22515, targeting Thyroid Eye Disease, an autoimm...
Merck acquires CN201 from Curon Biopharmaceutical
1 October 2024 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has completed the acquisition of CN201, an investigationa...
Adicet Bio announces enrollment for Phase 1 trial to evaluate ADI-001 in autoimmune diseases
30 September 2024 - Biotechnology company Adicet Bio Inc (NASDAQ: ACET) announced on Monday that it has opened enrollment for a Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases, includ...